Lilly adds another sales channel for obesity drug Zepbound
"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of rigorously tested, FDA-approved and regulated obesity treatment,” said Patrik Jonsson, president of Lilly Cardiometabolic Health and Lilly USA.
With the Biden administration pushing for Medicare, Medicaid coverage of GLP-1s, analysts disagree on whether it will ...
The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.
The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...
Medpage Today on MSN8d
Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly SaysAdults on the obesity medication tirzepatide (Zepbound) lost more weight on average than those on semaglutide (Wegovy) in a ...
Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.
The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...
GP leaders have warned that the rollout of the weight loss drug tirzepatide (Mounjaro, Eli Lilly) will still have ...
Tirzepatide has been shown in clinical trials to be more effective than diet and exercise support alone, and when compared ...
Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback